PeptiFinder Biotech scientist Yongjin Gong has presented a poster detailing the company's mRNA display platform, which enables in vitro selection of macrocyclic peptide binders. The platform features ultra-high-diversity libraries of up to 10^15 and achieves binding affinities ranging from high…
PeptiFinder Biotech has highlighted its mRNA display platform in a recent scientific poster, emphasizing the technology's ability to rapidly discover novel macrocyclic peptide binders with antibody-like affinities. The platform uses an in vitro selection and directed evolution approach that can potentially yield peptides with oral bioavailability.
The mRNA display platform from PeptiFinder Biotech supports a variety of peptide library formats, including linear, monocyclic, and bicyclic peptides. These libraries achieve ultra-high diversity levels reaching up to 10^15, which allows for rapid screening against nearly any biological target of interest.
The company incorporates unnatural amino acids into its macrocyclic peptide libraries. This approach can generate peptide hits that possess enhanced physicochemical properties and optimized pharmacokinetics, making them more suitable for therapeutic development.
According to the poster, the platform demonstrates robust performance across multiple target classes. Several case studies were presented that showcase the ability to generate peptide binders with affinities ranging from high nanomolar three-digit nM to picomolar pM levels. These binding strengths are comparable to those achieved by antibodies, yet macrocyclic peptides may offer additional advantages such as potential oral bioavailability.
The poster emphasizes the broad applicability of the mRNA display platform across diverse therapeutic modalities. By combining high-diversity screening with unnatural amino acid incorporation, PeptiFinder Biotech aims to create peptide candidates with improved drug-like properties.
PeptiFinder Biotech is scheduled to participate in the TIDES USA event, which will take place from April 26 to April 29, 2027, in Boston, Massachusetts. The event is described as North America's premier gathering for accelerating oligonucleotide and peptide innovations through collaborative discovery, development, and commercialization. Industry pioneers at TIDES USA explore strategies across oligonucleotides, peptides, mRNA, and genome editing to transform therapeutics from discovery to market reality.
Yongjin Gong, Scientist at PeptiFinder Biotech, authored the poster. Gong brings over 20 years of medicinal chemistry experience to the company, having contributed to two marketed drugs and multiple clinical candidates. His expertise includes structure-based drug design, structure-activity relationship SAR analysis, and organic synthesis. Gong holds both a Master of Science degree and a Master of Business Administration from Boston University.
The poster on mRNA display represents one of several scientific contributions from PeptiFinder Biotech, a company focused on peptide-based therapeutics. The platform's ability to achieve ultra-high diversity libraries up to 10^15 and generate binders with picomolar affinities positions it as a tool for discovering macrocyclic peptides that can target challenging biological targets.
The mRNA display technique described in the poster is a powerful in vitro selection and directed evolution method. It enables the discovery of novel macrocyclic peptide binders that can achieve antibody-like affinities while potentially offering oral bioavailability. This combination of properties is attractive for developing therapeutics that combine the specificity of biologics with the convenience of small molecules.
PeptiFinder Biotech's platform incorporates both natural and unnatural amino acids into peptide libraries. The use of unnatural amino acids can enhance the stability, binding affinity, and pharmacokinetic profile of the resulting peptides. The platform allows for linear, monocyclic, and bicyclic peptide formats, each offering different structural constraints that can affect binding properties.
The case studies mentioned in the poster demonstrate the platform's effectiveness across diverse target classes, though specific targets were not disclosed in the abstract. The affinities achieved, ranging from high nanomolar to picomolar, indicate that the platform can generate highly potent binders comparable to monoclonal antibodies.
The TIDES USA event in April 2027 will provide an opportunity for PeptiFinder Biotech to present more detailed data from their mRNA display platform. The conference, focused on accelerating oligonucleotide and peptide innovations, will bring together industry leaders to discuss strategies across multiple modalities including mRNA and genome editing.
PeptiFinder Biotech continues to develop its platform capabilities, aiming to address the growing demand for novel peptide therapeutics. The company's expertise in medicinal chemistry, combined with its high-diversity library technology, positions it to contribute to the field of macrocyclic peptide drug discovery.
Related reading: Study on Peptide Ligand Discovery for GPCRs Published in Nature, PCSK9 Peptide Vaccine Shows Sustained LDL Reduction in Preclinical Studies, Common Misunderstandings in Peptide Synthesis Explained, Peptide Vaccine Shows Promise for KRAS-Mutant Pancreatic Cancer.